DK0702560T3 - Immunforstærkning ved intermitterende interleukin-2 behandling - Google Patents

Immunforstærkning ved intermitterende interleukin-2 behandling

Info

Publication number
DK0702560T3
DK0702560T3 DK94920673T DK94920673T DK0702560T3 DK 0702560 T3 DK0702560 T3 DK 0702560T3 DK 94920673 T DK94920673 T DK 94920673T DK 94920673 T DK94920673 T DK 94920673T DK 0702560 T3 DK0702560 T3 DK 0702560T3
Authority
DK
Denmark
Prior art keywords
period
therapy
intermittent
treatment
infusions
Prior art date
Application number
DK94920673T
Other languages
Danish (da)
English (en)
Inventor
H Clifford Lane
Joseph A Kovacs
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0702560T3 publication Critical patent/DK0702560T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK94920673T 1993-05-19 1994-05-19 Immunforstærkning ved intermitterende interleukin-2 behandling DK0702560T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/063,315 US5419900A (en) 1993-05-19 1993-05-19 Immunologic enhancement with intermittent interleukin-2 therapy
PCT/US1994/005397 WO1994026293A1 (fr) 1993-05-19 1994-05-19 Facilitation immunologique par une therapie intermittente a l'interleukine-2

Publications (1)

Publication Number Publication Date
DK0702560T3 true DK0702560T3 (da) 2002-02-25

Family

ID=22048393

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94920673T DK0702560T3 (da) 1993-05-19 1994-05-19 Immunforstærkning ved intermitterende interleukin-2 behandling

Country Status (11)

Country Link
US (3) US5419900A (fr)
EP (1) EP0702560B1 (fr)
JP (1) JP4275193B2 (fr)
AT (1) ATE208206T1 (fr)
AU (1) AU691504B2 (fr)
CA (1) CA2163219A1 (fr)
DE (1) DE69428992T2 (fr)
DK (1) DK0702560T3 (fr)
ES (1) ES2167370T3 (fr)
PT (1) PT702560E (fr)
WO (1) WO1994026293A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
RU2117472C1 (ru) * 1995-08-22 1998-08-20 Андрей Юрьевич Егоров Противоопухолевое средство местно-резорбтивного действия на основе интерлейкина-2 человека
JP2002515730A (ja) * 1995-10-16 2002-05-28 カイロン コーポレイション 遺伝子発現を変調する因子のスクリーニング方法
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6498006B2 (en) * 1997-11-24 2002-12-24 Johnson T. Wong Methods for treatment of HIV and other infections using A T cell or viral activator and anti-retroviral combination therapy
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
AU2001287820A1 (en) * 2000-09-08 2002-03-22 Aventis Pasteur Use of lipopeptides for immunotherapy of hiv-positive subjects
FR2813793B1 (fr) * 2000-09-08 2003-01-24 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US6579521B2 (en) * 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
EP2280074A3 (fr) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
EP1411770A4 (fr) * 2001-07-05 2006-05-10 Chiron Corp Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
WO2003015697A2 (fr) * 2001-08-13 2003-02-27 University Of Southern California Mutants d'interleukine-2 a toxicite reduite
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (fr) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
JP5015601B2 (ja) 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
CA2700573C (fr) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Vaccins comprenant des antigenes de cellules souches cancereuses et procedes
CA2700436C (fr) 2006-09-28 2017-04-18 John S. Yu Vaccins contre le cancer et methodes de vaccination
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
EP2427485B1 (fr) 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Epitopes des cd133
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (fr) 2009-10-29 2011-05-19 Trustees Of Dartmouth College Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t
WO2013033626A2 (fr) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Produits thérapeutiques ciblant un récepteur nkp30
WO2013169691A1 (fr) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anticorps anti-b7-h6, protéines de fusion, et leurs procédés d'utilisation
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
WO2016057651A1 (fr) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
WO2021146436A2 (fr) 2020-01-14 2021-07-22 Synthekine, Inc. Méthodes et compositions de mutéines d'il2 biaisées

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4863730A (en) 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
US4868157A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4866157A (en) * 1987-11-10 1989-09-12 Sugio Otani Thermosetting aromatic resin composition
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
WO1991011719A1 (fr) 1990-01-26 1991-08-08 Washington Research Foundation Reactivite immune envers des oncogenes exprimes actives pour le diagnostic et le traitement de malignites
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5696079A (en) 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy

Also Published As

Publication number Publication date
CA2163219A1 (fr) 1994-11-24
US6190656B1 (en) 2001-02-20
PT702560E (pt) 2002-04-29
JP4275193B2 (ja) 2009-06-10
US6548055B1 (en) 2003-04-15
AU691504B2 (en) 1998-05-21
US5419900A (en) 1995-05-30
DE69428992D1 (de) 2001-12-13
EP0702560A1 (fr) 1996-03-27
WO1994026293A1 (fr) 1994-11-24
DE69428992T2 (de) 2002-08-14
AU7137794A (en) 1994-12-12
JPH09500362A (ja) 1997-01-14
EP0702560B1 (fr) 2001-11-07
ATE208206T1 (de) 2001-11-15
ES2167370T3 (es) 2002-05-16

Similar Documents

Publication Publication Date Title
DK0702560T3 (da) Immunforstærkning ved intermitterende interleukin-2 behandling
DK0504177T3 (da) IL-11, et pattedyrcytokin
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
MY103212A (en) Zinc-protamine-alpha interferon complex
ATE272708T1 (de) Immunregulation über die cd28-route
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
EP0625991A4 (fr) Composition amelioree d'alpha interferon et procede de preparation a partir de leucocytes peripheriques humains.
DK0911033T3 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
EP0177910A3 (fr) Application de préparations contenant de l'interféron-gamma (IFN-gamma) pour le traitement systématique de différentes maladies humaines à dose réduite
DE69030880D1 (de) Zusammensetzung zur Stimulierung des Immunsystems
ES2125233T3 (es) Tratamiento de las infecciones retrovirales humanas con 2',3'-didesoxiinosina.
DK0626177T3 (da) Ernæring til personer inficeret med humant immundefekt-virus
ES2078893T3 (es) Sistema de entrega de drogas transdermica pulsatoria.
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
IT8521468A0 (it) Procedimento per ottenere interferon leucocitario alfa-2dell'uomo.
FR2662942B1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
RU95104171A (ru) Средство для лечения иммуносупрессии при сепсисе у человека и способ ее лечения
Rosztóczy et al. Effects of interferons-α,-β, and-γ on human interleukin-2 production
Lane et al. Immunologic enhancement with intermittent interleukin-2 therapy
DK0651649T3 (da) Fremgangsmåde til administrering af opløsninger af granulocytkolonistimulerende faktor
Yokoyama et al. Role of lymphocyte activation by substance P in rheumatoid arthritis
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
Tank et al. Therapy with high dose recombinant alpha 2 interferon (IFN-alpha 2) produces a depression in natural killer cell cytotoxicity